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ABSTRACT 
Background and objective: 
 Admission white blood cell (WBC) count and Random Blood Sugar glucose 
(RBS) have been associated with adverse outcomes after acute myocardial 
infarction (AMI). This study investigated the combined effect of WBC count and 
Random Blood Sugar on predicting in-hospital mortality in patients with acute 
myocardial infarction. 
Material and methods:  
80 consecutive patients presenting with acute ST elevation myocardial infarction 
admitted in IMCU/ICCU Thanjavur Medical College Hospital from January 2014 
to August 2014 were studied. Patients satisfied the inclusion criteria underwent 
detailed history and clinical examination. WBC count and RBS were measured at 
the time of hospital admission and the patients were stratified into 3 groups (low, 
medium, and high) based on their WBC count and blood glucose. 
Results : 
 Patients with a high RBS had a four fold increase in in-hospital mortality and the 
patients with a high WBC count had a ten fold increase in mortality when 
compared with those with normal values. When a combination of different strata 
for each variable was analyzed, a stepwise increase in mortality was seen. Patients 
with high WBC count and normal RBS level or with a normal WBC count and 
high RBS values had intermediate risk. Multivariate analysis was performed to 
assess the predictors for in-hospital mortality using WBC count and RBS level as 
continuous variables and it showed these two were independently associated with 
in-hospital mortality. 
Conclusion: W.B.C count and plasma glucose level at admission has a prognostic 
importance in predicting in-hospital mortality in acute myocardial infarction. 
Keywords: MI-Myocardial infarction ; W.B.C – White blood cell ; RBS- Random 
blood sugar. 
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                                         INTRODUCTION: 
Ischemic heart disease is one of the most common non-
communicable disease causing mortality, morbidity and incurs great 
economic burden both in the developed and developing countries. Its 
incidence is on the rise due to sedentary lifestyle and increasing 
urbanization. In the next ten years it is going to be the most common 
cause of death worldwide.  
 It has been found in the recent years that the non- diabetic patients 
with acute myocardial infarction present with hyperglycemia, glycosuria 
and insulin resistance due to neurohumoral activation. Even though it is a 
physiological adaptive response; several studies in the recent past had 
shown that the high blood sugar values were associated with poor 
outcome in these patients.  
Several epidemiological studies have demonstrated the elevated 
levels of highly sensitive C- reactive protein, Interleukin-1b , Interleukin 
6 and tumour necrosis factor in ischemic heart disease patients and their 
levels peak during the event of acute coronary syndrome.  
The routine traditional risk factors like advanced age, smoking, 
diabetes, hypertension, dyslipidemia has been paid much attention and 
the role of inflammatory markers and stress hyperglycemia were 
neglected. 
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The total white blood cell count and the blood sugar values are 
frequently found elevated during the time of admission in acute coronary 
syndromes. Hyperglycemia may be due to pre-existing diabetes or due to 
simple stress hyperglycemia. The leukocytes are elevated physiologically 
as an adaptive response that is essential for wound healing and repair. 
Any exaggerated physiological response may always have some 
pathological consequences that is applicable here also. Hyperglycemia 
can produce free radical injury of myocytes, prevent blood flow in the 
occluded coronary vessels during reperfusion , dysfunction of vascular 
endothelium. Similarly elevated leukocyte count may promote 
coagulation, prevents micro vascular reflow, exaggerates inflammation 
and myocyte injury.  
Hence an elevated levels of  blood sugar levels and WBC count at 
the time of event in acute coronary syndrome usually have poor 
prognosis in terms of high in hospital mortality and decreased ejection 
fraction. The independent association of these two variables with 
prognosis have been evaluated in many other studies previously. 
 Determination of blood sugar and WBC count is a simple 
procedure, requires no expertise, is inexpensive and importantly, it is a 
correctable factor. Based on conflicting literature and because of lack of 
similar studies conducted in our region, this study aims at exploring the 
association between the admission glycemic status and and leukocyte 
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count with in- hospital mortality in acute ST elevation myocardial 
infarction patients. Hence this is a novel study that assess the combined 
effect of blood glucose and WBC count in predicting the complications 
and mortality of  ST elevation myocardial infarction patients. 
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AIMS AND OBJECTIVES: 
                                         The study is designed to assess; 
 the prognostic significance of white blood cell count and plasma 
glucose levels at admission in acute ST elevation myocardial 
infarction within 48 hours in terms of in –hospital mortality, 
 the  significance of white blood cell count and plasma glucose 
levels on predicting the cardiac functioning capacity in terms of 
Ejection Fraction during the hospital stay. 
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REVIEW OF LITERATURE: 
ANATOMY OF HEART: 
Fig 1: HEART AND CORONARY VESSELS- ANTEROR VIEW 
 
 The right cardiac border  formed  mainly  by the right atrium is 
convex and in line with the superior vena cava an inferior vena 
cava. 
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 The inferior border is formed mostly by the right ventricle and a 
small portion of the left ventricle. 
 The left border is formed predominantly by the left ventricle and a 
small portion of the left auricular appendages. 
 The main  pulmonary artery bifurcates into a right pulmonary 
artery that passes under the aortic arch and left pulmonary artery. 
 The right and left pulmonary veins open into the posterior wall of 
left atrium as four in number. 
CORONARY ARTERIAL SUPPLY: 
 The right and left coronary arteries : major blood vessels are the 
branches  from  ascending aorta in  anterior and posterior sinuses .  
 The Right coronary artery travels in the coronary sulcus to reach 
the posterior surface of the heart, where it anastomoses with the 
circumflex branch of the left coronary artery. It gives off the 
1)Sinoatrial (SA) nodal artery that supplies the right atrium and 
SA node;  2)Marginal branch supplying most of the anterior wall 
of the right ventricle, 3)Atrioventricular nodal artery near the 
posterior border of the interventricular septum, and 4)posterior 
interventricular artery in the interventricular groove that 
anastomoses with the anterior interventricular artery. 
 Left coronary artery gives the following branches 1)Circumflex 
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artery that passes posteriorly to anastomose with right coronary 
artery and 2) Anterior descending branch in the interventricular 
groove.The interventricular septum receives its blood supply from 
septal branches of the both descending arteries:-the anterior 2/3rd 
from the left coronary and the posterior 1/3 rd from the right 
coronary artery.  
 
Fig 2: HEART AND CORONARY VESSELS- POSTERO 
INFERIOR VIEW 
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 The term 'dominant system ' is usually to denote the predominance of  the right or left 
coronary in supplying the heart. It is decided by the artery which gives rise to 
posterior interventricular branch ; in 70- 75% of the individuals it is usually the left 
coronary artery. This posterior interventricular artery supplies the posterior two thirds 
of the interventricular septum. 
  Coronary arteries are end arteries during adult life. Collateral will develop only in 
stages of chronic hypoxia. But the situation is reverse during fetal life in that they 
will have rich collateral network. 
 
Control of Coronary Blood Flow: 
1. Local metabolism 
2. Nervous control 
1) Local metbolism of myocardium: 
 The factors responseible are: 
a) Oxygen Demand: 
A major factor of all: As oxygen extraction is near complete in resting state 
only, increase in oxygen demand has to be met with by increasing the blood 
flow. This is achieved  by the following mechanisms: 
1. Vasodilator Theory: Anoxia will liberate many vasodilator materials 
from myocardial cells which increase the blood flow: 
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i) Adenosine 
ii) Potassium ion 
iii) Hydrogen ion 
iv) Carbon dioxide 
v) Bradykinin and possibly 
vi) Prostaglindins 
2. Arterial Smooth Muscle Relaxation Theory: Decrease in oxygen supply 
leads to anoxia of coronary arterial smooth muscle cells, which loses their 
tone thus getting the artery dilated. 
 Factors that determine the oxygen consumption are: 
i) Increased arterial pressure, increases the work load and hence tension. 
ii) Dilatation of the heart increases the tension development in 
myocardium to pump the blood according to Laplace law, which states 
that tension required to generate a given pressure increases in 
proportion to the diameter of the heart. 
iii) Other factors which increases the oxygen consumption like stimulation of 
the heart by epinephrine and norepinephrine, thyroxine, digitalis, calcium 
ions, increased temperature of heart, will increase the oxygen 
consumption. 
iv) Reactive hyperemia: Anoxia brings about increase flow because of 
coronary dilatation after a brief period of coronary occlusion. 
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 Nervous Control 
a) Indirect: Sympathetics increases the heart rate and contractility, through 
the local metabolic mechanisms, and hence increases the coronary flow. 
Parasympathetics decrease the heart rate and depresses the 
myocardium and hence brings about coronary constriction. 
b) Direct Effect: 
Parasympathetics: As the vagal supply to ventricles is negligible, except for 
slight dilatation which may occur, there is no effect of its stimulation. 
Sympathetics: Epinephrine and norepinephrine through their receptors in 
coronary vessels usually bring about vasoconstriction or no change. When 
alpha effect dominates, severe constriction occurs which may bring about 
anginal attack. 
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DEFINITION OF MYOCARDIAL INFARCTION: 
In 2001 the American College of Cardiology  issued a joint recommendation for the 
diagnosis of Acute MI replacing the old version of World Health Organization definition.  
The typical rise and fall of cardiac markers like troponin or creatinine kinase  myocardial 
band subunit in addition to at least any one of the below finding:  
   
•     Symptoms typically suggestive of myocardial ischemia like prolonged angina, 
palpitation, diaphoresis. 
   
•     Electrocardiographic  changes indicating myocardial ischemia (ST-segment 
depression or elevation) 
   •     New onset deep pathological  Q waves 
 Pathologic findings of AMI at autopsy are also considered diagnostic(1). Additionally, any 
patient presenting with a clinical picture  consistent with myocardial infarction  with a 
combination of  new onset left bundle branch block can be  be considered  as STEMI. 
Detectable elevations of markers like troponin and CK-MB may not be apparent in those 
presenting within the first few  hours (4- 6hours )of onset of the event. Based on these 
guidelines , the distinction  between UA and NSTEMI may not be possible at the time of 
initial evaluation and  require serial measurements of cardiac biomarkers. 
MYOCARDIAL INFARCTION 
EPIDEMIOLOGY 
18 
 
Ischemic heart disease (IHD) is a condition in which there is an mismatch between the 
available blood supply of myocardium and oxygen demand of that area. It is caused by 
either obstruction to the blood flow in a coronary vessel or increased metabolic demands of 
myocardium like cardiac chamber hypertrophy. Myocardial infarction is the ischemic   
necrosis of myocardium. 
The most common etiology of MI  is atherosclerotic narrowing or obstruction  of an 
epicardial coronary artery that is sufficient to cause a regional reduction in myocardial 
blood flow and inadequate perfusion of the myocardium in that area. 
 
 
IHD causes more mortality and morbidity throughout the world and also makes a great 
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economic burden over the government. In the United States nearly 1.5 crore  persons have 
IHD,among which  more than 70 lakhs people have angina pectoris, and >7 million have 
sustained a attack of myocardial infarction in his lifetime. The early mortality i.e death 
within one month of  acute myocardial infarction is nearly 35- 40%, with majority of  
deaths occurring before the affected individual reaches the hospital Despite these sobering 
data, it is worth noting that epidemiologic data show a decline in the rate of deaths due to 
IHD, about half of which is attributable to treatments and half to prevention by risk factor 
modification(2). 
Obesity including metabolic syndrome , genetic factors like familial hyperlipidemias, high 
fat/ calory rich diet, sedentary life habits, insulin resistance, and type 2 diabetes mellitus are 
imajor  risk factors for IHD. South east  Asian countries are the population with high 
susceptibility. 
PATHOPHYSIOLOGY: 
                           Atherosclerotic plaque usually contains a central lipid core surrounded by a 
fibrous cap. Inflammation in the plaque recruits white blood cells mainly monocytes from 
the blood stream. Enzymes released from these monocytes cause oxidation of LDL . 
chemotactic factors from these leukocytes recruits more and more cells from the blood that 
intensifies the inflammation. Growth factors from these cells causes proliferation of smooth 
muscle cells in the media. Finally the metalloproteases released causes thinning , erosion 
and rupture of the fibrous cap that completely occludes the blood vessel lumen(3). 
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Fig 3: MECHANISM OF ATHEROMATOUS PLAQUE FORMATION: 
 
  
Major Risk Factors for Atherosclerosis 
NONMODIFIABLE  
    Advance  age that includes men more than 45 years and  women more than 55 years 
    Male gender 
    Positive Family history of  early onset CAD (at age less than 55 years) 
    Genetic abnormalities  
MODIFIABLE  
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Hyperlipidemia 
                               Total cholesterol > 150mg% 
Triglycerides > 150 mgs% 
LDL cholesterol > 100 mg% 
APO – b lipoproteins >100 mg % 
HDL cholesterol < 40 mg% males, < 50 mg% females. 
    Hypertension  
    Cigarette smoking  
    Diabetes Mellitus  
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    C-reactive protein  
    Apple obesity or BMI > 22    
    Homocysteine > 10 micro mol/lit 
STAGES OF ATHEROSCLEROSIS: 
Early atherosclerosis 
Subtle atherosclerosis 
Advance atherosclerosis 
Unstable coronary plaque(5) 
Fig 4: STAGES OF ATHEROSCLEROSIS: 
s  
 
VIRCHOWs TRIAD OF THROMBUS FORMATION:  
Virchows triad that is proposed for any vascular thrombus formation is applicable for 
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coronary thrombosis also. It includes hypercoagulable states as in familial thrombophilias 
like homocystinemia; abnormal vascular endothelium as in atherosclerosis; and vascular 
stasis in condition such as atrial fibrillation and severe ventricular dysfunction(4).  
Fig 5: VIRCOWs TRIAD: 
 
 
Causes of Acute MI: 
CORONARY ATHEROSCLEROSIS:Almost all MI’s result from coronary atherosclerosis  
NON ATHEROSCLEROTIC CORONARY ARTERY DISEASE(6) 
Arteritis as in collagen vascular disorders 
Traumatic injury of the coronaries 
 
Intimal Proliferative disease 
 Mucopolysaccharidoses 
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 Homocysteinemia 
 Fabry disease 
 Amyloidosis 
 Juvenile intimal sclerosis 
 Oral contraceptive pills 
 
Luminal narrowing 
 prinzmetals angina ; spasm without thrombus  
 Nitroglycerin withdrawal 
 Aortic Dissection 
 
Coronary artery Embolism 
 Acute bacterial endocarditis 
 Libman sachs and marantic  endocarditis 
 left ventricular stasis/ thrombus 
 Cardiac tumours 
 Post procedures like CABG and PTCA 
 
Congenital anomalies 
  ALCAPA 
 
Myocardial oxygen demand-supply mismatch 
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 Aortic stenosis,  
 Cardiac chamber hypertrophy 
 Severe anaemia 
 Pagets disease 
 Cardiogenic shock 
NATURAL HISTORY OF MYOCADIAL INFARCTION: 
 
 
 
 
PATHOPHYSIOLOGY OF ACUTE CORONARY SYNDROME: 
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                                                The clinical picture of acute coronary syndrome may vary 
depending upon the fate of the ruptured atherosclerotic plaque,(7) 
 Complete occlusion results in transmural ( ST  elevation) MI 
 Partial occlusion results in unstable angina / non ST elevation MI 
 Sometimes spontaneous resolution can occur 
 
 
HAEMODYNAMIC ALTERATIONS IN MI: 
                                                    Myocardial infarction results in decreased contractility of 
heart and there by reduced stroke volume that stimulates the baroreceptors to increase the 
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sympathetic outflow. This sympathetic surge increases the heart rate, increases afterload, 
and decreases the diastolic filling that results in a vicious cycle. 
 
  
 
 
CLINICAL FEATURES: 
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OTHER SYMPTOMS  
Diaphoresis, nausea, and vomiting , cold peripheries, delirium, giddiness, abdominal 
discomfort, unexplained syncopal attacks(8). 
SIGNS: 
Rapid thready (low volume) pulse 
Elevated blood pressure due to pain 
Low blood pressure due to cardiogenic shock 
Elevated jugular venous pulse 
Peripheral and central cyanosis 
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Febrile because of ongoing inflammation 
Tachypnoea in left ventricular dysfunction 
Tachycardia or bradycardia( inferior wall MI) 
Lung crepitations in pulmonary edema 
Muffled heart sounds especially S1 
Systolic murmur due to ventricular septal rupture or papillary muscle rupture 
LABORATORY INVESTIGATIONS : 
ELECTROCARDIOGRAM 
The 12 lead electrocardiogram should be done for all patients presenting with chest pain as 
early as possible. It does not mean that a  normal ECG does excludes the presence of 
myocardial infarction.The ECG provides critical information for both diagnosis and 
prognosis. 
STEMI is characterized by at least 1 mm/ 1mv elevation of  ST-segment in two or more 
contiguous chest leads. Reciprocal ST-segment depression in the leads away from the 
region of infarct further strengthens the diagnosis(9). 
 A right-sided ECG particularly RV3, RV4 should be obtained to exclude right ventricular 
infarction especially in inferior wall MI.  
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Marked 
ST depression in leads V1 to V3 with upright T waves indicates  posterior wall infarction, 
which is confirmed by ST-segment elevation in VR7 to VR9 leads. This should be 
suspected in every case of inferior wall MI. 
Patients presenting with  new onset left bundle branch block fulfilling sgarbossa criteria can 
be managed as  managed as anterior wall STEMI.  
Other disease entities with associated ST-segment elevation should be kept in mind like 
pericarditis, myocarditis, left ventricular aneurysm, early repolarization, coronary artery 
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spasm, intracranial bleeding, head trauma and left ventricular apical ballooning syndrome. 
Fig 6: SUBENDOCARDIAL AND TRANSMURAL INFARCT: 
 
Patients with NSTEMI can present with marked or minimal ST-segment depression or 
isolated T wave changes. This identifies patients at higher risk who subsequently benefit 
most from an aggressive management strategy(10). 
Nonspecific ST-segment and T wave abnormalities are usually defined as lesser amounts of 
ST-segment deviation or T wave inversion of 0.2 mV or less, and are less helpful for risk 
stratification . 
Diffuse ST-segment elevation and PR-segment depression suggest pericarditis. 
Fig 7: ST ELEVATION ANTERIOR AND INFERIOR WALL MI: 
32 
 
 
 
 Table 1: Infarct-Related Artery and Distribution of  ST-Segment Elevation(11) 
Location of Coronary 
Occlusion 
Distribution of ST-
Segment Elevation 
30-Day Mortality with 
Successful Reperfusion[*] 
Proximal LAD (proximal to 
first septal perforator) 
V1-V6, aVL, I, new LBBB 
common 
19.6% 
Middle LAD (distal to S1 
branch and proximal to D1 
branch) 
V1-V6, aVL, I, 9.2% 
Distal LAD (distal to origin of 
D1 branch) or diagonal branch 
V1-V4, or aVL, I, V5-6 6.8% 
Right coronary artery II, III, aVF, V5-6 (V3R, 6.4% 
33 
 
V4R with RV infarction) 
Left circumflex V5-6, III, II, aVF (can have 
minimal ECG changes) 
4.5% 
 
CHEST RADIOGRAPHY : 
A chest radiograph is typically obtained in all patients presenting with chest pain. It is 
usually nondiagnostic of ACS but show pulmonary edema caused by ischemic diastolic or 
systolic dysfunction. It is more useful for diagnosing other disorders mimicking ACS for 
example; aortic dissection(12). 
SERUM CARDIAC BIOMARKERS: 
Cardiac bio markers are intracellular enzymes or proteins released into the blood in 
from necrotic  dissolution of heart muscle after infarction(13). 
Rapid kits for cardiac markers are now available widespread. 
 
Table 2: FEATURES OF SERUM CARDIAC MARKERS ; 
  Sensitivity at: 
Marker Time to 
Appearance 
Duration 
of 
Elevation 
6 hr 12 hr Specificity Comments 
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Troponin 
I 
2–6 hr 5–10 days ∼75% 90–
100% 
∼98% Generally regarded as 
test of choice 
Troponin 
T 
2–6 hr 5–14 days ∼80% 95–
100% 
∼95% Test of choice; less 
specific than troponin I 
(elevated in renal 
insufficiency) 
CK-MB 3–6 hr 2–4 days ∼65% ∼95% ∼95% Test of choice for 
recurrent angina once 
troponin is elevated 
  
 
(1) Creatine phosphokinase (CPK) : 
It starts rising  after four to eight 8 hours and falls to basal level by 48hours  to 72 hours. It 
is more cheap and readily available. The only disadvantage is its non specific nature. It may 
be high in skeletal muscle disorders also. To overcome this issue is the use of ratio of MB 
subunit of creatine phosphikinase to the whole of creatine phosphokinase makes it more 
specific.  
   (2) Cardiac-specific troponin T (cTnT) and troponin I (cTnI)  
These levels are undetectable in normal individuals but it is elevated in STEMI upto twenty 
times higher. They are now the preferred biochemical markers for a small MI that is below 
the detection limit for CKMB measurements. Their Levels  remain high for 7 to 10 days 
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after the event. So they are less valuable in diagnosing reinfarction within one week. 
         (3) Myoglobin 
 It is the first enzyme to be released into the bllod after the onset of infarction. Because of 
its non specificity, rapid excretion, rapid fall of levels it is usually not preferred as a marker 
in myocardial infarction. 
(4) Non specific markers like leukocytosis especially neutrophills and eosinophills which 
appears in the first day itself and persists for 3 to 7 days. The ESR rises more slowly ; peaks 
during the 1st  week and remains elevated for 3 to 4 weeks. 
 
FIG 8. PATTERN OF ENZYME ELEVATION IN MYOCARDIAL INFARCTION
 
CARDIAC IMAGING 
ECHOCARDIGRAPHY 
Random wall motion abnormalities in 2D ECHO are almost universally present.  
The disadvantage is the acute STEMI cannot be differentiated from an 
old scar(14). 
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 Echocardiography  is useful in assessing left ventricular ejection fraction, diastolic 
dysfunction, mural thrombus, ventricular aneurysm, chamber hypertrophy. 
It is also useful in diagnosing the complications like pericarditis, dressler syndrome, 
ventricular septal rupture and mgurgitation.  
RADIONUCLIDE TECHNIQUE 
(1) Myocardial perfusion imaging with 201Thallium  or 99mTechnitium-sestamibi reveal a 
perfusion defect as cold spot  in myocardial infaction. It can detect very earlier than 
enzymes but it is too expensive and it also cannot differentiate new oinfarction from old 
scar. 
POSITRON EMISSION TOMOGRAPHY 
PET scanning uses positron emitting agents to demonstrate alterations in the metabolism of 
myocardium. PET can easily differentiate stunned  myocardium due to acute ischemia from 
an old scar .18 fluoro deoxy glucose is used as a marter . A nearby cyclotron is required to 
produce this 18 FDG tracer.  
CORONARY ARTERIOGRAPHY 
Coronary arteriography is indicated in (1)  chronic stable angina people  pectoris who are 
having severe symptoms inspite of adequate medical therapy(2) patients with troublesome 
symptoms and unconfirmed diagnosis in whom to rule out the diagnosis of IHD, (3) patients 
with angina pectoris who have experienced cardiac arrest and survived (4) patients with 
features of IHD on other non invasive testing with clinical or laboratory evidence of 
ventricular dysfunction(16) . 
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Noninvasive alternatives include CT angiography and cardiac MR angiography .Higher 
radiation exposure with CT angiography compared to conventional diagnostic arteriography 
and the artefacts on cardiac MR imposed by cardiac movement during the cardiac cycle 
especially at high heart rates are limitations. 
STRESS TESTING:  
An.All medications including beta blockers, nitrates should be discontinued one day 
prior to the test. The patient is allowed to exercise upto 85% of maximum predictable heart 
rate and a 12 lead ECG should be performed. A new ST depression of more than 2mm ; 
inability to exercise for more than two minutes; development of hypotension, arrhythmia, 
heart failure are the endpoints. stress testing can also be performed pharmacologically by 
using dipyridamole, adenosine and dobutamine (15).  
RISK STRATIFICATION AND PROGNOSIS: 
 Table 3:Thrombolysis in MI Risk Score for Unstable Angina/NSTEMI 
One Point score for each of the Following: Score 
Risk of Adverse 
Event[*] 
Age ≥65 years 0/1 4.7% 
Presence of =3 CV risk factors 2 8.3% 
Recent (<24 h) severe angina 3 13.2% 
Known coronary stenosis ≥50% 4 19.9% 
ST-segment deviation on admission ECG ≥0.5 mm 5 26.2% 
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Use of aspirin within past 7 days 6/7 40.9% 
Elevated biomarkers of cardiac injury (troponin, CK-
MB) 
    
Abbreviations: CV = cardiovascular; ECG = electrocardiogram. 
 
 
 
 
 
 
 
Table 4:Thrombolysis in MI  Score for STEMI: 
Various Risk Factors Points Total Score 30-Day Mortality rate (%) 
Patient Age ≥75 years 3 0 0.8 
Patient Age 65-74 years 2 1 1.6 
Systolic Blood Pressure <100 mm Hg 3 2 2.2 
Pulse rate>100 beats/min 2 3 4.4 
Killip class more than 1 2 4 7.3 
Anterior MI or LBBB 1 5 12.4 
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Diabetes mellitus, HTN, or angina 1 6 16.1 
Weight <67 kg 1 7 23.4 
Symptom onset to treatment >4 h 1 8 26.8 
    >8 35.9 
Abbreviations: BP = blood pressure; HTN =hypertension; LBBB = left bundle branch 
block; MI = myocardial infarction 
COMPLICATIONS OF MYOCARDIAL INFARCTION: 
Fig 9: VARIOUS COMPLICATIONS OF MYOCARDIAL INFARCTION: 
 
 
TREATMENT: 
The initial treatment of patients presenting with AMI are:  
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    Obtain intravenous (IV) access and stabilize hemodynamics if unstable. 
    Relieve ischemic pain using IV morphine and sublingual or IV NTG. 
  
   Minimize myocardial oxygen demand – supply mismatch with IV β-blockers 
(heart rate <70 bpm as blood pressure tolerates) and supplemental oxygen. 
  
   Maintain myocardial perfusion using aspirin and heparin (either IV 
unfractionated or subcutaneous LMWH). 
Patients with STEMI should receive prompt reperfusion therapy (thrombolysis or 
primary percutaneous intervention)  
Aspirin  
All patients should receive 324 mg of aspirin (four 81 mg tablets chewed and swallowed or 
as  rectal suppository ) and continue at 81 mg daily thereafter. In patients with STEMI, 
aspirin reduces mortality to a similar extent as thrombolytic therapy, Aspirin-allergic 
patients should receive 300 mg of clopidogrel. 
Clopidogrel  
Clopidogrel blocks the platelet ADP receptor .It is a prodrug converted into its active form 
in liver.A 300-mg loading dose is administered followed by 75 mg daily. Administer 600 
mg loading of clopidogrel in ACS patients planned for Percutaneous coronary intervention. 
Clopidogrel combined with aspirin, compared with aspirin alone, reduces the risk of 
cardiovascular death, recurrent  infarction, or stroke in patients with NSTEMI patients who 
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donot undergo percutaneous revascularization .Clopidogrel, 75 mg daily, should be 
continued for at least 9months -1year following percutaneous coronary revascularization. If 
coronary angiography is not anticipated, clopidogrel should be continued for 9 to 12 
months.  
Heparin  
Patients presenting with Acute MI should be treated with either IV unfractionated heparin :   
60 IU/kg intravenous  bolus followed by 12 IU/kg /hour iv infusion or subcutaneous low-
molecular-weight heparin (LMWH) except for STEMI patients receiving streptokinase. In 
STEMI, IVUFH is required to maintain vessel patency in those receiving a fibrin-specific 
thrombolytic agent (alteplase, reteplase, and tenecteplase). Administration ofLMWH 
reduces the risk of death and ischemic events compared with IV UFH in patients with 
NSTEMI and inunstable angina. LMWH appears safe when continued up until the time of 
coronary angiography and percutaneous intervention.LMWH should not be givento patients 
with significant renal failure (creatinine clearance < 50 mL / min) or morbid obesity(17). 
β-Blockers  
All patients with Acute MI should receive prompt oral β-blocker therapy to be continued 
indefinitely in the absence of contraindications. Metoprolol is preferred in the acute setting 
because of short half-life compared with atenolol. β-blockers are beneficial due to their 
ability to reduce oxygen supply-demand mismatch by reducing heart rate, reducing 
myocardial contraction, and reducing arterial BP . β-blockers also reduce the risk of atrial 
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and ventricular tachyarrythmias and reduce the risk of  ventricular free wall rupture. 
Nitroglycerin  
Nitroglycerin can be administered as a sublingual formulation or as IV infusion. 
Nitroglycerin does not improve prognosis in AMI and should be used cautiously  in patients 
with right ventricular or inferior wall MI that could result in hypotension. Nitroglycerin 
should not be given to the patients who have taken Viagra or other PDE inhibitor within 24 
hours. 
Glycoprotein IIb/IIIa Inhibitors  
These agents block the GP IIb/IIIa platelet receptor, which functions as the receptor for 
fibrinogen adherence. They reduce ischemic complications associated with PCI and should 
be administered in patients for whom an early invasive strategy is planned. Benefit is shown 
with eptifibatide (Integrilin) and tirofiban (Aggrastat) in patients with NSTEMI ACS who 
do not undergo early PCI. This benefit appears isolated to high-risk patients including those 
with troponin elevation, ST-segment depression > 0.5 mV, diabetes mellitus, and LVEF< 
40%.  
HMG-CoA Reductase Inhibitors (Statins)  
Early, aggressive statin therapy improves the clinical outcomes. Previous trials showed that 
intensive atorvastatin therapy with 80 mg daily initiated following ACS significantly 
reduces adverse cardiac events compared with less intensive statin therapy .A recent trial 
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(ARMYDA-ACS) demonstrated that pretreatment with atorvastatin 80 mg 12 hours prior to 
Percutaneous Coronary Intrvention gives  around 90% reduction in adverse cardiac events 
and significantly reduced peri-procedural MI rates. 
REPERFUSION THERAPY IN STEMI:  
Regardless of the modality of reperfusion used, the time from symptom onset to myocardial 
reperfusion has the strongest influence on myocardial salvage, recovery of myocardial 
function, and improvements in mortality. Patients receiving successful reperfusion within 
three hours of symptom onset receives the greatest benefit. 
Thrombolysis  
Thrombolytic therapy is the most commonly utilized method of reperfusion worldwide. The 
fibrin-specific t-PA derived thrombolytic agents (alteplase reteplase and tenecteplase ) have 
proved superior but significantly more expensive than the fibrin-nonspecific agents such as 
streptokinase. The fibrin-specific agents reduce 30-day mortality rate that is similar rates of 
successful reperfusion with streptokinase. Clinically,successful thrombolysis is associated 
with resolution of chest symptoms and reduction of ST-segment height by atleast50%. 
Patients with persistent symptoms, persistence of ST-segment elevation and hemodynamic 
collapse following thrombolysis should be referred for emergency PCI(18).  
Thrombolytic Agents 
 Streptokinase 
 Reteplase 
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 Alteplase 
 Tenecteplase 
 
  
TABLE 5: CONTRAINDICATIONS OF THROMBOLYSIS(19): 
Contraindications for Thrombolytic Administration 
Absolute  
   •     Prior ICH 
   •     Ischemic stroke less than  3 months duration 
   •     Ongoing active bleeding anywhere except  menstruation 
   •     Significant head or facial injury less than 3 months 
   •     Possible or doubtful aortic dissection 
   •     Intracranial neoplasm 
   •     Intracranial vascular structural abnormality 
Relative  
   •      Internal bleed in the recent past i.e within 4 week 
   •     Major internal  surgery within 3 week 
   •     History of ischemic stroke 
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   •      prolonged  Cardio Pulmonary Resuscitation of more than 10 minutes 
   •     Pregnancy 
   •     Patients on anticoagulants with INR >2.0 
   •     Noncompressible vascular puncture 
   •     Accelerated hypertension BP >180/110 mm Hg 
   •     Active peptic ulcer disease 
   •     Prior streptokinase exposure (for repeat streptokinase administration) 
 
 
PERCUTANEOUS CORONARY INTERVENTION (PCI) IN STEMI: 
                               Primary PCI  including coronary artery stenting of the artery is  superior 
to thrombolysis when done by experienced operators in high-volume centers with less 
("door-to-balloon") time i.e < 90 min. 
Primary PCI is the treatment of choice in patients with contraindications to thrombolytic 
therapy. Stenting; along with the glycoprotein IIb/IIIa antagonist abciximab—is now widely 
used in patients with acute myocardial infarction.  
In the patients with cardiogenic shock, early catheterization and percutaneous or surgical 
revascularization are the preferred mode of approach now a days. This carries a lower risk 
of hemorrhagic complications. 
Facilitated PCI is an approach in which a combination of  fibrinolytic agents either in full or 
half the dose is given and is followed by immediate PCI(20). 
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METABOLIC ABNORMALITIES IN DIABETES: 
ABNORMAL MUSCLE AND FAT METABOLISM 
Insulin resistance, the decreased ability of insulin to act effectively on target tissues 
(especially muscle, liver, and fat), is a prominent feature of type 2 DM and results from a 
combination of genetic susceptibility and obesity. Insulin resistance is relative, however, 
since supranormal levels of circulating insulin will normalize the plasma glucose. Insulin 
dose-response curves exhibit a rightward shift, indicating reduced sensitivity, and a reduced 
maximal response, indicating an overall decrease in maximum glucose utilization (30–60% 
lower than in normal individuals). Insulin resistance impairs glucose utilization by insulin-
sensitive tissues and increases hepatic glucose output; both effects contribute to the 
hyperglycemia. Increased hepatic glucose output predominantly accounts for increased FPG 
levels, whereas decreased peripheral glucose usage results in postprandial hyperglycemia. 
In skeletal muscle, there is a greater impairment in nonoxidative glucose usage (glycogen 
formation) than in oxidative glucose metabolism through glycolysis. Glucose metabolism in 
insulin-independent tissues is not altered in type 2 DM(21). 
The precise molecular mechanism leading to insulin resistance in type 2 DM has not been 
elucidated. Insulin receptor levels and tyrosine kinase activity in skeletal muscle are 
reduced, but these alterations are most likely secondary to hyperinsulinemia and are not a 
primary defect. Therefore, "postreceptor" defects in insulin-regulated 
phosphorylation/dephosphorylation appear to play the predominant role in insulin 
47 
 
resistance. For example, a PI-3-kinase signaling defect might reduce translocation of 
GLUT4 to the plasma membrane. Other abnormalities include the accumulation of lipid 
within skeletal myocytes, which may impair mitochondrial oxidative phosphorylation and 
reduce insulin-stimulated mitochondrial ATP production. Impaired fatty acid oxidation and 
lipid accumulation within skeletal myocytes also may generate reactive oxygen species such 
as lipid peroxides. Of note, not all insulin signal transduction pathways are resistant to the 
effects of insulin (e.g., those controlling cell growth and differentiation using the mitogenic-
activated protein kinase pathway). Consequently, hyperinsulinemia may increase the insulin 
action through these pathways, potentially accelerating diabetes-related conditions such as 
atherosclerosis.(22) 
The obesity accompanying type 2 DM, particularly in a central or visceral location, is 
thought to be part of the pathogenic process. The increased adipocyte mass leads to 
increased levels of circulating free fatty acids and other fat cell products .For example, 
adipocytes secrete a number of biologic products (nonesterified free fatty acids, retinol-
binding protein 4, leptin, TNF- , resistin, and adiponectin). In addition to regulating body 
weight, appetite, and energy expenditure, adipokines also modulate insulin sensitivity. The 
increased production of free fatty acids and some adipokines may cause insulin resistance in 
skeletal muscle and liver. For example, free fatty acids impair glucose utilization in skeletal 
muscle, promote glucose production by the liver, and impair beta cell function. In contrast, 
the production by adipocytes of adiponectin, an insulin-sensitizing peptide, is reduced in 
obesity, and this may contribute to hepatic insulin resistance. Adipocyte products and 
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adipokines also produce an inflammatory state and may explain why markers of 
inflammation such as IL-6 and C-reactive protein are often elevated in type 2 DM. In 
addition, inflammatory cells have been found infiltrating adipose tissue. Inhibition of 
inflammatory signaling pathways such as the nuclear factor B (NF-kB) pathway appears to 
reduce insulin resistance and improve hyper-glycemia in animal models.(23) 
IMPAIRED INSULIN SECRETION: 
In type 2 DM, insulin secretion initially increases in response to insulin resistance to 
maintain normal glucose tolerance. Initially, the insulin secretory defect is mild and 
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selectively involves glucose-stimulated insulin secretion. The response to other 
nonglucosesecretagogues, such as arginine, is preserved. Abnormalities in proinsulin 
processing is reflected by increased secretion of proinsulin in type 2 diabetes. Eventually, 
the insulin secretory defect progresses to a state of inadequate insulin secretion. 
The reason(s) for the decline in insulin secretory capacity in type 2 DM is unclear. The 
assumption is that a second genetic defect—superimposed upon insulin resistance—leads to 
beta cell failure. Beta cell mass is decreased by approximately 50% in individuals with 
long-standing type 2 diabetes. Islet amyloid polypeptide or amylin is co-secreted by the beta 
cell and forms the amyloid fibrillar deposit found in the islets of individuals with long-
standing type 2 DM. Whether such islet amyloid deposits are a primary or secondary event 
is not known. The metabolic environment of diabetes may also negatively impact islet 
function. For example, chronic hyperglycemia paradoxically impairs islet function 
("glucose toxicity") and leads to a worsening of hyperglycemia. Improvement in glycemic 
control is often associated with improved islet function. In addition, elevation of free fatty 
acid levels ("lipotoxicity") and dietary fat may also worsen islet function. 
INCREASED HEPATIC GLUCOSE AND LIPID PRODUCTION 
In type 2 DM, insulin resistance in the liver reflects the failure of hyperinsulinemia to 
suppress gluconeogenesis, which results in fasting hyperglycemia and decreased glycogen 
storage by the liver in the postprandial state. Increased hepatic glucose production occurs 
early in the course of diabetes, though likely after the onset of insulin secretory 
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abnormalities and insulin resistance in skeletal muscle. As a result of insulin resistance in 
adipose tissue, lipolysis and free fatty acid flux from adipocytes are increased, leading to 
increased lipid [very low density lipoprotein (VLDL) and triglyceride] synthesis in 
hepatocytes(44). This lipid storage or steatosis in the liver may lead to nonalcoholic fatty 
liver disease and abnormal liver function tests. This is also responsible for the dyslipidemia 
found in type 2 DM [elevated triglycerides, reduced high-density lipoprotein (HDL), and 
increased small dense low-density lipoprotein (LDL) particles]. 
INSULIN RESISTANCE SYNDROMES 
The insulin resistance condition comprises a spectrum of disorders, with hyperglycemia 
representing one of the most readily diagnosed features. The metabolic syndrome, the 
insulin resistance syndrome, or syndrome X are terms used to describe a constellation of 
metabolic derangements that includes insulin resistance, hypertension, dyslipidemia 
(decreased HDL and elevated triglycerides), central or visceral obesity, type 2 diabetes or 
IGT/IFG, and accelerated cardiovascular disease(41).  
A number of relatively rare forms of severe insulin resistance include features of type 2 DM 
or IGT (Table 344-1). Mutations in the insulin receptor that interfere with binding or signal 
transduction are a rare cause of insulin resistance. Acanthosisnigricans and signs of 
hyperandrogenism (hirsutism, acne, and oligomenorrhea in women) are also common 
physical features. Two distinct syndromes of severe insulin resistance have been described 
in adults: (1) type A, which affects young women and is characterized by severe 
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hyperinsulinemia, obesity, and features of hyperandrogenism; and (2) type B, which affects 
middle-aged women and is characterized by severe hyperinsulinemia, features of 
hyperandrogenism, and autoimmune disorders. Individuals with the type A insulin 
resistance syndrome have an undefined defect in the insulin-signaling pathway; individuals 
with the type B insulin resistance syndrome have autoantibodies directed at the insulin 
receptor. These receptor autoantibodies may block insulin binding or may stimulate the 
insulin receptor, leading to intermittent hypoglycemia. 
Polycystic ovary syndrome (PCOS) is a common disorder that affects premenopausal 
women and is characterized by chronic anovulation and hyperandrogenism . Insulin 
resistance is seen in a significant subset of women with PCOS, and the disorder 
substantially increases the risk for type 2 DM, independent of the effects of obesity. 
 
 
HYPERGLYCEMIA IN MYOCARDIAL INFARCTION: 
The mortality and morbidity of  the diabetic patient sustaining a myocardial 
infarction is poor compared with that of non-diabetic patients.Studies have shown that 
hyperglycemia induces adverse prognosis even in non diabetic patients . Claure Bennard 
observed and explained acute hyperglycemic response to stress more than a century ago. 
“Diabetes of injury” concept evolved as glucose has been identified as metabolic mirror of 
the severity and outcome of critical illness.  
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PREDICTIVE VALUE OF PLASMA GLUCOSE IN MYOCARDIAL 
INFARCTION(24): 
 Elevated admission glucose levels in patients with acute myocardial infarction is 
independently associated with large infarct sizes. 
 A significant assosiation between hyperglycaemia at the time of infarction and the 
development of heart failure has been reported in large scale studies. 
 Admission Hyperglycemia  in MI is found to be associated with high heart rate in 
Acute Myocardial infarction. 
MECHANISM OF HYPERGLYCEMIA IN MI: 
The exact pathological mechanism of hyperglycaemia induced by Acute MI is unclear, 
although several explanations have been proposed 
FIG 10: MECHANISM OF STRESS HYPERGLYCEMIA: 
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.  
        Stress during the occurrence of myocardial infarction induces the secretion of adrenal 
steroids that have various adverse effects like increasing heart rate ; increasing myocardial 
oxygen demand; increasing glycogenolysis in the liver; suppressing insulin production; 
augmenting glucagon secretion.The resulting elevated blood sugar has adverse 
consequences on myocardium(25).  
 
VARIOUS EFFECTS OF ACUTE HYPERGLYCEMIA ON Acute MI:  
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Fig 11:  VARIOUS ADVERSE EFFECTS OF HYPERGLYCEMIA IN MI 
 
1. Electrophysiological changes:  
High blood gucose content in the blood induces some changes in resting membrane 
potential of cardiac myocytes. These changes produces a state of electrical instability which 
is superimposed on altered conduction during myocardial infarction. The final result will be 
occurrence of arrhythmias which could be fatal sometimes e.g Ventricular tachycardia. 
 2. Impaired left ventricular function:  
Acute hyperglycemia causes impaired left ventricular systolic function
 
which has been 
proved in various studies. The probable mechanism is the induction of vasospasm by 
glucose thet prevents the blood flow during reperfusion. Further hyperglycemia shifts the 
metabolism from glycolysis to fatty acid metabolism. 
FIG 12: MECHANISM OF HYPERGLYCEMIC MYOCARDIAL INJURY: 
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3. Effect on coagulation:  
 
IHyperglycemia by unknown mechanism induces platelet activation and aggregation; 
activation of extrinsic factors of coagulation and inhibits fibrinolysis.The net result is the 
prothrombotic state that promotes coronary occlusion.  
4. Effect on inflammatory immune reaction:  
Atherosclerosis itself is considered as a state of systemic inflammation. These patients are 
in a state of ongoing inflammation that rapidly progress to a peak level during the event of 
acute coronary syndrome. Acute MI patients usually have elevated levels of C-Reactive 
protein, ESR, Interleukin-18, Tumour Necrosis Factor in their blood(27). These substances 
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further causes damage of cardiac myocytes.  
5. Effect on endothelial function:  
Hyperglycemia diminishes the ability of endothelium to secrete nitric oxide which is a 
potent vasodilator. Further damage to the  vascular endothelium favours platelet activation 
and aggregation leading to the expansion of thrombus(26).   
6. Oxidative stress:  
Oxidative stress is a well known pathogenic process for atherosclerosis and cardiovascular 
diseases.
 
Free radical production by hyperglycemia is the probable pathologic process. Free 
radical injury is more common during the stage of reperfusion. It cause depletion of 
intracellular glutathione stores, mitochondrial dysfunction, lipid peroxidation of membranes 
and DNA damage. 
 
3-Nitrotyrosine , a marker of oxidative damage
 
and it has recently been 
demonstrated to be increased in monkeys during acute hyperglycemia(29) 
Fig 13: MECHANISM OF HYPERGLYCEMIC OXIDATIVE DAMAGE: 
.  
57 
 
 
LEUKOCYTES: 
Leukocytes are the nucleated blood cells which are mainly involved in the immune 
functions of the body(30). They are synthesized  in the bone marrow ( the granulocytes , 
monocytes ) and in the lymphoid tissue ( lymphocytes and plasma cells). 
TYPES OF LEUKOCYTES 
They are : 
1) Polymorphonuclear neutrophils 
2) Polymorphonuclear eosinophils 
3) Polymorphonuclear basophils 
4) Monocytes 
5) Lymphocytes 
6) Plasma cells 
CAUSES OF LEUKOCYTOSIS(31) 
NEUTROPHILIC LEUKOCYTOSIS 
1) Acute bacterial infections 
2) Tissue necrosis like  burns  and myocardial infarction. 
EOSINOPHILIC LEUKOCYTOSIS 
1) Parasitic infestations 
2) Malignancies – Hodgkins and NHL 
3) Vasculitis 
4)Allergic disorders 
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BASOPHILIC LEUKOCYTOSIS  
Myeloproliferative disorders - CML 
MONOCYTOSIS 
1) Chronic infections – tuberculosis 
2) Bacterial endocarditis 
3) Rickettsiosis 
4) Malaria 
5) Collagen vascular diseases (S.L.E) 
6) Inflammatory bowel disorders 
ROLE OF LEUKOCYTES IN ATHEROSCLEROSIS(32): 
                                                  After endothelial injury by an unknown initiating factor, 
white blood cells especially monocytes undergo margination and attach themselves to the 
vascular endothelium. These cells migrate into the sub endothelial space by diapedesis and 
gets deposited. This initiates the recruitment of more and more leukocytes into that area. 
These cells secrete some enzymes that converts LDL into oxidized LDL. These particles are 
taken up by the residing macrophages and gets converted into foam cells. The cytokines like 
TGF beta released from these cells causes the proliferation of smooth muscle cells in the 
tunica media and mediates their migration into fibrous cap of atheromatous plaque. The 
lipid core will enlarge in course of time and finally the Matrix Metallo Proteases , 
collagenase, elastase causes the degradation of the fibros cap that exposes the 
subendothelial core . The platelets gets attached and activated that leads to thrombus 
formation and vessel lumen obstruction.  
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Fig 13: ROLE OF WBC IN ATHEROSCLEROSIS: 
 
 
MECHANISM OF MYOCADIAL INJURY BY LEUKOCYTES(33): 
1)Endothelial injury 
2)Luminal obstruction  
3)Reduced myocyte blood supply 
4)Exaggerated leukocyte recruitment 
5)Increased expression of monocyte chemoattractant protein 
6)Clotting system overactivity 
7)Electrical instability 
8)Increased leukocyte adhesion. 
Proteolytic and oxidative vascular damage 
This is mainly mediated by polymorphs. These cells secrete elastase, hyaluronidase, 
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collagenase and other proteolytic enzymes that causes detachment of vascular endothelial 
cells. This makes the platelets easy for their attachment in the exposed subendothelium and 
formation of thrombus. chemokines released from these cells recruites more leukocytes. 
Free radicals released from these cells further causes endothelial damage. 
Vessel plugging 
The intensification of inflammation causes synthesis and  recruitement of more 
lymphocytes that are abnormal in their function and morphology. These cells are more rigid 
, large in size, more sticky that makes them to plug and occlude the blood vessel. The 
narrowing of lumen by the plaque further worsens the situation(36). 
Abnormal leukocyte aggregation 
Leukocytes also have surface receptors similar to other cells. These receptors get activated 
in the presence of chemokines tht leads to their stasis , aggregation , and destruction that 
leads to further release of mediators.Rise in hematocrit also contributes to the effect. 
Leukocytes and infarct expansion 
The mechanism of infarct expansion includes two different phenomenon. After the blood 
flow is restored more leukocytes enter into the affected area that aggravates the 
microvascular plugging and prevents the reflow pattern. The other one is the entry of more 
leukocytes and increased oxygen tension in that area leads to production of more reactive 
oxygen species that further damages cardiac myocytes and endothelium through free radical 
mediated injury.These processes contributes to the expansion of infarction. 
Fig 14: ROLE OF INFLAMMATORY CYTOKINES IN MYOCARDIAL INJURY: 
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Leukocytes and hypercoagulability(34) 
There is a linear association between the total leukocyte count and the coagulant activity of 
the blood. The leukocytes especially monocytes are involved in the activation of platelets. 
These monocytes can also take part in forming the platform for coagulation cascade. 
Leukocytes activates the extrinsic clotting factors especially factor 7 and factor 8. 
Interleukins released from these cells also activates complement system that promotes 
coagulation.  
Leukocytes and reperfusion 
High leukocyte count increases the thrombin formation through the interaction between P 
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selectin , vascular endothelial adhesion molecule, and intercellular adhesion molecule. This 
increased thrombin burden resist the physiological fibrinolytic system. 
Leukocytes and electrical instability 
Leukocyte through the free radicals alter the membrane potential of cardiac myocytes and 
the superimposed altered pattern conduction  that results in VT and VF.  
Fig :15 MECHANISM OF LEUKOCYTOSIS IN MYOCARDIAL INFARCTION: 
                                                     
  
                                          Myocardial infarction results in the release of inflammatory 
cytokines from the necrotic tissue that get attached to the activated B cell through CD 20 
and some unknown ligand . This process releases lymphokines that recruits more number of  
lymphocytes and monocytes from the bonemarrow resulting in myocardial injury 
Free Radical Injury: 
ROS are capable of causing irreversible damage to  all biochemical compounds 
Of the cell including lipids, nucleic acids, proteins, carbohydrates and connective tissues. 
ROS has an effect on membrane function also. ROS are thought to be involved in 
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causation of many clinical conditions like acute glomerulonephritis, cancer, 
atherosclerosis and Parkinson’s disease. 
Oxidative stress is capable of inducing oxidation of lipids and in the presence of oxygen, 
lipid peroxidation of cell membranes. It is generally accepted that lipid oxidation proceeds 
via a free radical induced mechanism called autooxidation, which induces initiation, 
propagation, and termination stages and predominantly occurs with PUFA. Polyunsaturated 
acyl chains of membrane phospholipids are particularly sensitive to lipid peroxidation. 
Lipid oxidation, both nonenzymatic and enzymatic, is self propagating in cellular 
membrane. Peroxidation of PUFA is classically depicted as a series of three or 
four basic reactions; however, the process becomes more complex as both the degree of 
unsaturation and severity of peroxidative conditions increases(35).  
 
Lipid peroxidation causes loss of membrane fluidity, membrane potential, 
increases the membrane permeability of Ca2+ and causes loss of membrane 
integrity. MDA is formed by fatty acids with three or more double bonds and is 
used as a measure of lipid peroxidation 
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  MATERIALS AND METHODS 
SOURCE OF DATA 
80 consecutive patients presenting with acute ST Elevation myocardial infarction admitted 
to IMCU/ ICCU Thanjvur Medical College Hospital from January 2014 to August 2014 
were studied. 
SAMPLE SIZE 
Size of the sample n= 80 
p = prevalence rate 
q = 1-p 
INCLUSION CRITERIA 
                 Patients admitted in IMCU/ICCU  
1)presenting within 48 hrs of symptom onset. 
2) Anginal Chest pain lasting more than 30 minutes. 
3) Characteristic ECG changes with ST segment elevation more than 1mm  in limb leads or  
more than 2mm in two contiguous chest leads 
EXCLUSION CRITERIA 
1)Patients presenting after 48 hours of symptom onset. 
2)Patients receiving drugs/iv fluids elevating blood glucose levels.  
3)Post surgical or post traumatic up to one month. 
COLLECTION OF DATA: 
Random blood glucose level was measured at the time of admission. It is estimated by 
65 
 
glucose oxidase glucose peroxidase technique. 
3ml of  EDTA mixed blood sample  was collected and subjected to complete blood  count – 
both total and differential count by automated coulter counter and  by manual examination. 
PATIENT STRATIFICATION: 
Patients were grouped into 3 categories according to their admission blood glucose levels, 
 
Blood glucose Group I: Random blood sugar < 130 mg%,  
Blood glucose Group II: Random blood sugar 131- 180 mg%, and 
Blood glucose Group III: Random blood sugar >I80 mg%  
 
Patients were grouped into 3 categories according to their admission blood glucose levels,  
            WBC Group I: Total count < 8000 cells/ cu mm.  
WBC Group II: Total count 8000-11000/ cu mm and 
WBC  Group III: Total count >11000 cu/mm.  
 
STUDY END POINTS : 
The primary end point of the study is all cause mortality during the period of stay in the 
hospital.  
STATISTICAL METHODS: 
Data was analyzed by using following statistical methods, 
1. Diagrammatic (bar / pie chart)representation 
2. Mean + standard deviation (SD) 
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3. Chi square test for non continuous variables 
4. Analysis of variance for continuous variables 
5. Multivariate analysis tests to determine the association between W.B.C 
count and blood glucose levels with in hospital mortality. 
 
INVESTIGATIONS 
 
A) Blood 
Haemoglobin 
Total count 
Differential count 
 
B) Urine: 
Albumin 
Sugar 
Microscopy 
 
C) Biochemistry 
Random blood glucose on admission 
Urea , 
Serum  creatinine 
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D) 12 lead Electrocardiography (ECG) 
E) 2D Echocardiography – Ejection fraction 
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RESULTS AND STATISTICS: 
Table 6: AGE DISTRIBUTION OF PATIENTS: 
Particulars 
No.of respondents 
(n=80) 
Percentage 
(100%) 
Below 40yrs 7 8.8 
41 to 50yrs 14 17.5 
51 to 60yrs 29 36.3 
61 to 70yrs 21 26.3 
71yrs & above 9 11.3 
 
Graph1: BAR DIAGRAM OF AGE DISTRIBUTION OF 
PATIENTS : 
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Table 7: SEX DISTRIBUTION OF PATIENTS: 
Particulars 
No.of 
respondents 
(n=80) 
Percentage 
(100%) 
Male 62 77.5 
Female 18 22.5 
 
Graph2: BAR DIAGRAM OF SEX DISTRIBUTION OF 
PATIENTS 
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Table 8: DISTRIBUTION OF SMOKERS IN STUDY GROUP: 
 
Particulars 
No.of respondents 
(n=80) 
Percentage 
(100%) 
No 33 41.3 
Yes 47 58.8 
 
Graph3: DISTRIBUTION OF SMOKERS IN STUDY GROUP: 
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Table 9: DISTRIBUTION OF DIABETICS IN STUDY GROUP: 
Particulars 
No.of 
respondents 
(n=80) 
Percentage 
(100%) 
No 31 38.8 
Yes 49 61.3 
 
Graph4: DISTRIBUTION OF DIABETICS IN STUDY GROUP:
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Table 10: DISTRIBUTION OF HYPERTENSIVE PATIENTS IN 
STUDY GROUP: 
Particulars 
No.of 
respondents 
(n=80) 
Percentage 
(100%) 
No 37 46.3 
Yes 43 53.8 
 
Graph5: DISTRIBUTION OF HYPERTENSIVE PATIENTS IN 
STUDY GROUP: 
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Table 11: DISTRIBUTION OF KNOWN IHD PATIENTS IN 
STUDY GROUP: 
Particulars 
No.of 
respondents 
(n=80) 
Percentage 
(100%) 
No 36 45.0 
Yes 44 55.0 
 
Graph6: DISTRIBUTION OF KNOWN IHD PATIENTS IN 
STUDY GROUP: 
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Table 12: DISTRIBUTION OF PATIENTS ACCORDING TO 
KILLIP CLASS: 
Particulars 
Number 
(n=80) 
Percentage 
(100%) 
1 31 38.8 
2 31 38.8 
3 14 17.5 
4 4 5.0 
 
Graph7: DISTRIBUTION OF PATIENTS ACCORDING TO 
KILLIP s 
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TABLE 13:  DISTRIBUTION OF THE THROMBOLYSED 
PATIENTS: 
Particulars 
No.of 
respondents 
(n=80) 
Percentage 
(100%) 
Negative 26 32.5 
Positive 54 67.5 
 
Graph8: DISTRIBUTION OF THE THROMBOLYSED 
PATIENTS: 
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Table 14: DISTRIBUTION OF PATIENTS IN WBC <8000 GROUP  
WBC< 8000 & (RBS<130) 
Particulars 
No.of 
subjects 
(n=80) 
Percentage 
(100%) 
No 65 81.3 
Yes 15 18.8 
 
WBC< 8000 & (RBS130-180) 
Particulars 
No.of respondents 
(n=80) 
Percentage 
(100%) 
No 66 82.5 
Yes 14 17.5 
 
In the WBC group1 i.e. WBC count <8000/ cu mm. the number of 
deaths in RBS<130 mg subgroup was 0 ; in RBS 130- 180mg subgroup 
was 1(6.7%) and in RBS>180mg  subgroup was 4(26.7%) and the chi 
square analysis showed there is a significant association of the last 
subgroup with the mortality (p = 0.017). 
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WBC< 8000 & (RBS>180) 
Particulars 
No.of 
respondents 
(n=80) 
Percentage 
(100%) 
No 72 90.0 
Yes 8 10.0 
 
Graph9: DISTRIBUTION OF PATIENTS IN WBC <8000 GROUP  
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Table 15: DISTRIBUTION OF PATIENTS IN WBC 8000- 11000 
GROUP  
WBC- 8000-11000 (RBS<130) 
Particulars 
No.of respondents 
(n=80) 
Percentage 
(100%) 
No 64 80.0 
Yes 16 20.0 
 
WBC- 8000-11000 (RBS130-180) 
Particulars 
No.of respondents 
(n=80) 
Percentage 
(100%) 
No 68 85.0 
Yes 12 15.0 
 
                                                            In the WBC group2 i.e. WBC count 
8000-11000 cells / cu mm. the number of deaths in RBS<130 mg 
subgroup was 0 ; in RBS 130- 180mg subgroup was 3(20.0%) and in 
RBS>180mg  subgroup was 4(26.7%) and the chi square analysis 
showed there is a significant association of the  2nd and 3rd subgroup with 
the mortality (p = 0.039) and (p = 0.032) respectively. 
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WBC- 8000-11000 (RBS>180) 
Particulars 
No.of respondents 
(n=80) 
Percentage 
(100%) 
No 75 93.8 
Yes 5 6.3 
  
Graph 10::DISTRIBUTION OF PATIENTS IN WBC 8000- 11000 
GROUP  
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Table 16: DISTRIBUTION OF PATIENTS IN WBC >11000 
GROUP  
WBC> 11000 (RBS<130) 
Particulars 
No.of respondents 
(n=80) 
Percentage 
(100%) 
No 78 97.5 
Yes 2 2.5 
 
WBC> 11000 (RBS130-180) 
Particulars 
No.of respondents 
(n=80) 
Percentage 
(100%) 
No 75 93.8 
Yes 5 6.3 
 
                                                                 In the WBC group3 i.e. WBC 
count >11000/ cu mm. the number of deaths in RBS<130 mg subgroup 
was 0 ; in RBS 130- 180mg subgroup was 1(6.7%) and in RBS>180mg  
subgroup was 7(46.7%) and the chi square analysis showed there is a 
significant association of the last subgroup with the mortality (p = 0.001) 
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WBC> 11000 (RBS>180) 
Particulars 
No.of respondents 
(n=80) 
Percentage 
(100%) 
No 73 91.3 
Yes 7 8.8 
 
Graph 10: DISTRIBUTION OF PATIENTS IN WBC >11000 
GROUP  
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Table 17: FREQUENCY TABLE OF TERRITOTY INVOLVED: 
Particulars 
No.of respondents 
(n=80) 
Percentage 
(100%) 
ASMI 3 3.8 
AWMI 50 62.5 
IWMI 25 31.3 
RVMI 2 2.5 
 
Graph 11:FREQUENCY  OF TERRITOTY INVOLVED: 
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TABLE 18: OUTCOME -DEATH(D) RECOVERY ( R ) 
Particulars 
No.of 
respondents 
(n=80) 
Percentage 
(100%) 
Death 15 18.8 
Live 65 81.3 
 
Graph 12: BAR DIAGERM SHOWING THE OUTCOME: 
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Tab19: FREQUENCY DISTRIBUTION OF AGE & EJECTION 
FRACTION: 
Item  Min Max Mean  S.D 
AGE 28 85 57.83 11.280 
EJECTION 
FRACTION(%) 
29 58 48.64 6.592 
Graph 13: FREQUENCY DISTRIBUTION OF AGE & EJECTION 
FRACTION:
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Tab 20: CHI SQUARE TEST FOR MORTALITY IN SMOKERS: 
SMOKIN
G 
Death Live Total Statistic
al 
inference 
(n=15
) 
(100%
) 
(n=65
) 
(100%
) 
(n=80
) 
(100%
) 
No 8 53.3% 25 38.5% 33 41.3% X2=1.112 
Df=1 
.292>0.0
5 
Not 
Significa
nt 
 
Yes 7 46.7% 40 61.5% 47 58.8% 
Graph 14: CHI SQUARE TEST FOR MORTALITY IN 
SMOKERS: 
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Our study contain 15 members among which smokers were 8 in number 
(53.3%) and non smokers were (46.7%) and the difference was 
statistically insignificant. 
Tab21: CHI SQUARE TEST FOR MORTALITY IN DIABETES: 
DIABETE
S 
Death Live Total Statistic
al 
inferenc
e 
(n=15
) 
(100%
) 
(n=65
) 
(100%
) 
(n=80
) 
(100%
) 
No 2 13.3% 29 44.6% 31 38.8% X2=5.025 
Df=1 
.025<0.0
5 
Significa
nt 
Yes 13 86.7% 36 55.4% 49 61.3% 
 
Graph 15 :CHI SQUARE TEST FOR MORTALITY IN DIAB
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Diabetic persons in the death group were 13 (86.7%) and 2 were non 
diabetics (13.3%) and the difference was statistically very significant chi 
square value =  5.025 Df = 1 and    p = 0.025(<0.05) 
Tab22: CHI SQUARE TEST FOR MORTALITY IN 
HYPERTENSION: 
HYPERTENSION 
Death Live Total Statistical 
inference (n=15) (100%) (n=65) (100%) (n=80) (100%) 
No 4 26.7% 33 50.8% 37 46.3% X2=2.848 
Df=1 
.091>0.05 
Not Significant 
Yes 11 73.3% 32 49.2% 43 53.8% 
Graph 16: CHI SQUARE FOR MORTALITY In HYPERTENSION: 
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Tab23 : CHI SQUARE TEST FOR MORTALITY IN WBC < 8000 
GROUP: 
RBS <130 mg% 
WBC< 
8000 
(RBS<130) 
Death Live Total Statistical 
inference (n=15) (100%) (n=65) (100%) (n=80) (100%) 
No 15 100.0% 50 76.9% 65 81.3% X2=4.206 
Df=1 
.039<0.05 
Significant 
Yes 0 .0% 15 23.1% 15 18.8% 
 
 
RBS 130 -180 mg% 
WBC< 
8000 
(RBS130-
180) 
Death Live Total 
Statistical 
inference (n=15) (100%) (n=65) (100%) (n=80) (100%) 
No 14 93.3% 52 80.0% 66 82.5% X2=1.501 
Df=1 
.221>0.05 
Not 
Significant 
Yes 1 6.7% 13 20.0% 14 17.5% 
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RBS >180 mg% 
WBC< 
8000-
11000 
(RBS>180) 
Death Live Total 
Statistical 
inference (n=15) (100%) (n=65) (100%) (n=80) (100%) 
No 11 73.3% 61 93.8% 72 90.0% X2=5.698 
Df=1 
.017<0.05 
Significant 
Yes 4 26.7% 4 6.2% 8 10.0% 
 
Graph 17 : CHI SQUARE TEST FOR MORTALITY IN WBC < 
8000 GROUP: 
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Tab 24: CHI SQUARE TEST FOR MORTALITY IN WBC 8000-
11000 GROUP: 
RBS <130 mg% 
WBC: 
8000-
11000 
(RBS<13
0) 
Death Live Total 
Statistica
l 
inference 
(n=15
) 
(100%
) 
(n=65
) 
(100%
) 
(n=80
) 
(100%
) 
No 15 100.0% 49 75.4% 64 80.0% 
X2=4.615 
Df=1 
.032<0.0
5 
Significa
nt 
Yes 0 .0% 16 24.6% 16 20.0% 
 
RBS 130- 180 MG% 
WBC: 
8000-
11000 
(RBS130
-180) 
Death Live Total 
Statistica
l 
inference 
(n=15
) 
(100%
) 
(n=65
) 
(100%
) 
(n=80
) 
(100%
) 
No 12 80.0% 56 86.2% 68 85.0% X2=.362 
Df=1 
.547>0.05 
Not 
Significa
nt 
Yes 3 20.0% 9 13.8% 12 15.0% 
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RBS  >180 mg% 
 Death Live Total 
Statistica
l 
inference 
WBC: 
8000-
11000 & 
(RBS>18
0) 
(n=15
) 
(100%
) 
(n=65
) 
(100%
) 
(n=80
) 
(100%
) 
No 12 80.0% 63 96.9% 75 93.8% X2=5.957 
Df=1 
.015<0.0
5 
Significa
nt 
Yes 3 20.0% 2 3.1% 5 6.3% 
 
Graph 18 : CHI SQUARE TEST FOR MORTALITY IN WBC 
8000- 11000 GROUP: 
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Tab 25: CHI SQUARE TEST FOR MORTALITY IN WBC >11000 
GROUP: 
RBS <130 mg% 
WBC> 
11000 & 
(RBS<130) 
Death Live Total Statistical 
inference (n=15) (100%) (n=65) (100%) (n=80) (100%) 
No 15 100.0% 63 96.9% 78 97.5% X2=.473 
Df=1 
.491>0.05 
Not 
Significant 
Yes 0 .0% 2 3.1% 2 2.5% 
RBS 130-180 mg % 
WBC> 
11000 & 
(RBS130-
180) 
Death Live Total 
Statistical 
inference (n=15) (100%) (n=65) (100%) (n=80) (100%) 
No 14 93.3% 61 93.8% 75 93.8% X2=.005 
Df=1 
.941>0.05 
Not 
signify 
Yes 1 6.7% 4 6.2% 5 6.3% 
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RBS >180 mg % 
WBC> 
11000 & 
(RBS>180) 
Death Live Total Statistical 
inference (n=15) (100%) (n=65) (100%) (n=80) (100%) 
No 8 53.3% 65 100.0% 73 91.3% X2=33.242 
Df=1 
.000<0.05 
Significant 
Yes 7 46.7% 0 .0% 7 8.8% 
 
 
Graph 19: CHI SQUARE TEST FOR MORTALITY IN WBC 
>11000 GROUP:
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Tab 26: CHI SQUARE TEST FOR MORTALITY IN VARIOUS 
CORONARY TERRITORIES: 
TERRITO
TY 
INVOLVE
D 
Death Live Total Statistic
al 
inferenc
e 
(n=1
5) 
(100
%) 
(n=6
5) 
(100
%) 
(n=8
0) 
(100
%) 
ASMI 0 .0% 3 4.6% 3 3.8% X2=2.80
6 Df=3 
.422>0.0
5 
Not 
Significa
nt  
AWMI 12 80.0% 38 58.5% 50 62.5% 
IWMI 3 20.0% 22 33.8% 25 31.3% 
RVMI 0 .0% 2 3.1% 2 2.5% 
 
Graph 20:CHI SQUARE TEST FOR MORTALITY IN VARIOUS 
CORONARY TERRITORIES:
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Tab 27: 
Variable Chi Square P Value 
   
Killips Class >2 X2=4.726 
    P=.000<0.05  Significant 
   
Age X2=3.545 
    P=.471>0.05   Not Significant 
   
WBC Count >11000   X2=33.242 
    P=.000<0.05  Significant 
   
RBS >180 X2=5.698 
    P=.017<0.05  Significant 
   
Prior IHD X2=1.015 
    P=.314>0.05  Not Significant  
   
Smoker X2=1.112 
    P=.292>0.05  Not Significant  
   
Diabetes mellitus X2=5.025 
    P=.025<0.05  Significant  
   
 Sex  X2=3.242 
    P=.072>0.05  Not Significant 
Hypertension X2=2.848 
    P=.091>0.05  Not Significant  
   
Territory involved X2=2.806 
    P=.422>0.05  Not Significant 
   
 
Multivariate analysis showed that WBC count and  random blood  glucose levels 
are independent predictors for in hospital mortality. 
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ANALYSIS OF RESULTS: 
                                   This study included 80 patients with ST elevation myocardial 
infarction admitted within 48 hours of symptom onset and their blood sugar values 
and total WBC counts were compared with the in-hospital mortality. 
                                    Our study group comprised of 62 males (77.5%) and 18 
females(22.5%). Smokers (n=47) constitute 51.2% of the study group. Patients 
who were already diabetics and taking treatment were 49 (61.2%). And 
hypertensives were 43 people(53.7%). The number of patients presenting with 
killip class 1, 2, 3, 4 were 31(38.8%), 31(31.8%), 14,(17.4%) and 4 (5.0%) 
respectively. Patients underwent thrombolysis were 54(67.5%) and conservatively 
managed were26(32.5%). 
                           The patients were stratified into three groups based on their 
blood sugar values and total white blood cell count.  
Blood glucose Group I: Random blood sugar < 130 mg%,  
Blood glucose Group II: Random blood sugar 131- 180 mg%, and 
Blood glucose Group III: Random blood sugar >I80 mg%  
WBC Group I: Total count < 8000 cells/ cu mm.  
WBC Group II: Total count 8000-11000/ cu mm and 
WBC  Group III: Total count >11000 cu/mm.  
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                                                       The total number of deaths during the hospital 
stay in our study contain 15 members among which smokers were 8 in number 
(53.3%) and non smokers were (46.7%) and the difference was statistically 
insignificant. Among the mortality group 9 (60.0%) were men and 6 (40.0%)were 
women and the sex difference was not statistically significant. Diabetic persons in 
the death group were 13 (86.7%) and 2 were non diabetics (13.3%) and the 
difference was statistically very significant chi square value =  5.025 Df = 1 and    
p = 0.025(<0.05) that shows the diabetic status influences the mortality in our 
study. Among the 80 patients the mean killip class of recovered patients were 3.0 
(SD = 0.756) and that of died people were 1.63( SD = 0.675) and the T value is 
6.927 ;  Df = 78 ; p = 0.001 that is significant statistically. So the patients admitted 
with high killip class succumb to the disease. 
                                                          In the WBC group1 i.e. WBC count <8000/ cu 
mm. the number of deaths in RBS<130 mg subgroup was 0 ; in RBS 130- 180mg 
subgroup was 1(6.7%) and in RBS>180mg  subgroup was 4(26.7%) and the chi 
square analysis showed there is a significant association of the last subgroup with 
the mortality (p = 0.017). 
                                                            In the WBC group2 i.e. WBC count 8000-
11000 cells / cu mm. the number of deaths in RBS<130 mg subgroup was 0 ; in 
RBS 130- 180mg subgroup was 3(20.0%) and in RBS>180mg  subgroup was 
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4(26.7%) and the chi square analysis showed there is a significant association of 
the  2nd and 3rd subgroup with the mortality (p = 0.039) and (p = 0.032) 
respectively. 
                                                                 In the WBC group3 i.e. WBC count 
>11000/ cu mm. the number of deaths in RBS<130 mg subgroup was 0 ; in RBS 
130- 180mg subgroup was 1(6.7%) and in RBS>180mg  subgroup was 7(46.7%) 
and the chi square analysis showed there is a significant association of the last 
subgroup with the mortality (p = 0.001) 
                                                                  There is also positive correlation between 
the mean Ejection fraction percentage among the people in these three groups.  In 
the WBC group1 i.e. WBC count <8000/ cu mm the mean ejection fraction  in 
RBS<130 mg subgroup was 51.67%  ; in RBS 130- 180mg subgroup was 48.50% 
and in RBS>180mg  subgroup was 42.0%. 
                                                                     Among the mortality group the number 
of persons in Anterior wall MI, Antero septal MI, Inferior  wall MI, Right 
ventricular MI were 12(80%) , 0(0%), 3(20%), 0(0%) respectively. Analysis 
showed a p value of 0.422 and hence there is no significant association between the 
territory involved and the outcome in our study. 
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                                                       DISCUSSION: 
                In our study we have included 80 cases of acute  ST elevation 
myocardial infarction presented to the hospital within 48 hours of onset of 
symptoms and got admitted in IMCU/ ICCU of thanjavur medical college hospital, 
during the period January2014- August 2014. 
The patient’s history was taken and physical examination findings were 
noted. At admission patient’s random blood glucose values, total WBC count, 12 
lead ECG, Echocardiogram were done. The patients were followed during the 
hospital stay and in-hospital complications like congestive cardiac failure and 
arrhythmias were noted. Death was the end point of the study.  
Admission RBS values, WBC count values , in hospital complications, 
ejection fraction and in- hospital mortality data were analyzed. Chi- square test and 
one way ANOVA with post hoc test were used to identify differences between the 
3 groups with their subgroups. 
The 80 patients that were studied had ST elevation acute myocardial 
infarction and  were divided into three groups 1-3 based on admission (RBS< 130 
mg%, RBS 131- 180 mg%, and RBS >I80 mg%. There were 3 subgroups in each 
group: WBC< 8000 cells/ cu mm, WBC count 8000-11000/ cu mm and WBC 
count >11000 cu/mm.  
. 
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 The mean age of the patients in our study group was 57.83 years. The mean 
age were compared between these three groups, which were statistically not 
significant. However previous studies have shown that as age advances there is 
high rates of  poor glycemic status, which may be responsible along with other risk 
factors.
 
 
There were a total of 62 males and 18 females in our study. The mortality 
rate was compared between the two sex groups which was not significant .But in a 
previous study by Kahderi et al women had high admission blood glucose  
compared to males of similar age and have higher mortality.
 
 
          In our study 43 patients had hypertension and were on treatment, 47 patients 
gave history of smoking and 44 patients were previously had coronary artery heart 
diasease and on treatment . There was no statistically significant difference in 
smokers, hypertensives and prior IHD patients and their mortality. Ranicho et al 
studied in 2002; an American community-based study showed the presence of high 
mortality in MI patients with history of smoking, hypertension and recurrent 
infarction patients. These results are not perfectly matched with ours, and this 
could be explained by the ethnic and genetic variations between Indian and 
American people. 
         The total number of diabetics in our study were 49 persons when we analysed 
the mortality among these people it was statistically very significant that shows the 
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diabetic status influences the mortality. Moreover there is a positive correlation 
between the blood glucose levels and a poor outcome as the patients in high blood 
glucose group had high killip class and low mean Left ventricular ejection fraction. 
These results were supported by many previous studies especially the one done by 
Hafiner et al in which the patients with diabetes have two times high incidence of  
myocardial infarction and these  patients also have four times high mortality 
compared to controls. Previous studies also showed that congestive cardiac failure 
is the main complication of diabetics with MI and this may also contribute to the 
outcome. 
           In our study the  patients with high blood glucose i.e RBS> 180 mg% have 
significant mortality nearly around 4 times compared to the low blood glucose 
groups even when adjusted for other risk factors.. These results were comparable 
to the previous studies done by Qiako et al in which he showed that in non diabetic 
patients with myocardial infarction  the association of 2 hours prandial blood 
glucose is an independent predictor of poor outcome and future coronary events.  
            The patients with high WBC count in our study have high mortality around 
10 times when compared to the medium and low count groups even when other 
confounding factors were eliminated. Our results were supported by a study done 
by Baranni et al . According to his study high  wbc count was associated with 
higher amplitude of ST elevation, high incidence of transmural infarcts, and high 
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incidence of  congestive cardiac failure, ventricular tachycardia and one year 
mortality rates. 
            Hence it was found that patients with high WBC count (> 11,000) at 
admission had a ten fold higher mortality rate than those patients having low WBC 
count (<8300). Similarly patients with high blood glucose level (>180mg%) had a 
four fold higher rate of mortality than those patients with low blood glucose(<130) 
. A multivariate analysis was done of various risk factors like smoking , advanced 
age, hypertension with mortality and we found that WBC counts and plasma  
glucose levels were independent  risk factors  in  acute myocardial  infarction. 
These results were in concordance with a study done by Iseikara et al who found 
out that  the patients with a high WBC count had a two fold increase in hospital 
mortality compared with those with a low W.B.C count and patients with high 
glucose level had a 2.7 fold increase in mortality compared to the low plasma 
glucose level. Another study done by  Morghan et al described a 9.4 fold higher 
mortality in patients with high WBC count and high glucose level at admission 
compared to those with low values. 
Several hypotheses were proposed  to explain the relation between  
hyperglycemia and poor outcome in myocardial infarction.  Hyperglycemia may be 
a marker of extensive myocardial damage, reflecting a surge of stress hormones 
such as catecholamines and cortisol that produce or accentuate an insulin-resistant 
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state.
 
These changes reduce glucose uptake by the ischemic myocardium and 
promote lipolysis and increased circulating  FFA- free fatty acids. The latter inhibit 
glucose oxidation by inhibiting aerobic glycolysis and are as such toxic to ischemic 
myocardium, resulting in increased membrane damage, arrhythmias, and reduced 
contractility and stroke volume.
 
Alternatively elevated blood glucose levels per se 
adversely affect outcome through the cumulative effects of several mechanisms, 
including induction of endothelial dysfunction,
 
oxidative stress,
 
hypercoagulability, 
and impaired fibrinolysis. 
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SUMMARY: 
 The maximum number of deaths occur in the age group of 51- 60 years.The 
mean age of the patients in our study group was 57.83 years. The mean age 
were compared between these three groups, which were statistically not 
significant. 
 There were a total of 77% males and 23% females in our study. The 
mortality rate was compared between the two sex groups which was not 
significant. 
 In our study 43 patients had hypertension , 47 patients gave history of 
smoking and 44 patients were previously had coronary artery heart diasease . 
There was no statistically significant difference in smokers, hypertensives 
and prior IHD patients and their mortality. 
 in our study the mortality among the diabetic patients was higher when 
compared with non diabetics and the association was statistically 
significant that shows the diabetic status influences the mortality. Moreover 
there is a positive correlation between the blood glucose levels and a poor 
outcome as the patients in high blood glucose group had high killip class and 
low mean Left ventricular ejection fraction. 
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 In our study the  patients with high blood glucose i.e RBS> 180 mg% have 
significant mortality nearly around 4 times compared to the low blood 
glucose groups even when adjusted for other risk factors.. 
 The patients with high WBC count (>11000) in our study have high 
mortality around 10 times when compared to the medium and low count 
groups even when other confounding factors were eliminated. 
 A multivariate analysis was done of various risk factors like smoking , 
advanced age, hypertension with mortality and we found that WBC counts 
and plasma  glucose levels were independent  risk factors  in  acute 
myocardial  infarction. 
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LIMITATIONS: 
 It is hospital based one step study. 
 Limited number of cases were studied. 
 Diabetic patients were not excluded from the study. 
 Chronic inflammatory conditions causing leukocytosis were not excluded 
 Patients were not followed up for future complications after discharge from 
the hospital. 
 Diagnosis of myocardial infarction was based on clinical features and ECG. 
Cardiac biomarkers were not done.  
  However the result of the study serve as a baseline for further study of blood 
sugar levels and WBC count in myocardial infarction and their inclusion in risk 
scoring systems..  
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CONCLUSION:  
Following conclusions were made after completion of this study:  
 Subjects with higher admission RBS(>180 mg%) either diabetic or non 
diabetic and those with high leukocyte count (>11000) were found to have 
high incidence of in-hospital mortality. 
 Elevated admission RBS and leukocytes levels are associated with increase 
in cardiac  complications and  poor cardiac function. 
 There was a positive linear correlation between admission RBS and WBC 
count values with the outcome of the patients. 
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                                       PROFORMA 
NAME:                                                                            IP. NO: 
AGE:                                                                                DOA: 
SEX:                                                                                 DOD: 
OCCUPATION:                                                               ADDRESS: 
MARITAL STATUS:                                                       
STATUS AT DISCHARGE: 
 
PRESENTING COMPLAINTS: 
I. HISTORY OF PRESENTING ILLNESS: 
A. CHEST PAIN: 
  Site: Precordial/ Restrosternal/Epigastric/ Shoulder/ Neck 
  Duration: 
  Nature: Squeezing/Crushing/Compressive/Tightness 
  Radiation: Arm/ Back/ Epigastric/ Neck 
  Frequency: 
  Aggravating Factor: 
  Relieving Factor: 
  Associated :sweating/ vomiting/palpitations/ breathlessness 
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B. BREATHLESSNESS: 
  Onset: Sudden/ Gradual Grade: I/II/III/IV 
  Orthopnea: Yes/ No 
  PND: Yes/No 
 
C. COUGH 
  Productive/ Non Productive 
  Haemoptysis: Yes/ NO 
 
D.SYNCOPAL ATTACKS: Yes/ No 
 
E. SWELLING OF LEGS/ FACE: Yes /No 
 
F. OLIGURIA : Yes /No 
 
G. CONVULSIONS: Yes /No 
 
H. OTHER SYMPTOMS: 
 
II. PAST HISTORY 
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HISTORY PRESENT/ABSENT DURATION TREATMENT 
IHD- Angina    
Infarction    
Diabetes    
Hypertension    
RHD    
Syphilis    
TIA/ Stroke    
 
III. PERSONAL HISTORY 
1. Diet: Vegetarian/ Mixed 
2. Bladder: Normal/ Polyuria/ Anuria/Dysuria 
5. Bowel: Normal/ Constipated /Loose stools 
6. Menstrual history :Normal/Irregular/ Postmenopausal 
7. Exposure to STD: Present/ Absent  
8. Habits              Duration           Type                   Quantity  
    Smoking :          
    Alcohol: 
    Tobacco Chewing : 
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IV. GENERAL PHYSICAL EXAMINATION 
1) Built Well/Moderate Poor 
2) Nourishment Obese/Average Poor 
3) Emotional state Calm/Anxious Restless 
4) Pallor Present/ Absent 
5) Cyanosis Present/ Absent 
6) Icterus Present/ Absent 
7) Clubbing Present/ Absent 
8) Pedal edema Present/ Absent 
9) Lymphadenopathy Present/ Absent 
10) Extremities Warm/ Cold 
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V. VITAL SIGNS 
Pulse 
Blood pressure 
Respiratory rate 
Temperature 
VI. SYSTEMIC EXAMINATION 
CVS EXAMINATION 
1) Pulse 
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Rate 
Rhythm 
Volume 
Character 
Condition of Vessel Wall 
Radio Femoral Delay 
2) JVP –Normal /Raised 
A. INSPECTION 
Precordium Normal/Bulged 
Apical impulse Visible / Non Visible 
Other pulsation 
B. PALPATION 
Apical impulse Location, Character 
Palpable Heart Sounds 
Thrills Apex 
Parasternal area 
Any other 
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C. PERCUSSION 
Cardiomegaly 
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Pericardial effusion 
D. AUSCULTATION 
Heart sounds 
S3/S4 Present/ Absent 
Murmur Timing/Location/Character/Radiation/Grade 
Pericardial rub 
Basal crepitations 
Others 
KILLIP CLASS: 
RESPIRATORY SYSTEM: 
PER ABDOMEN: 
CENTRAL NERVOUS SYSTEM 
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INVESTIGATIONS 
I. BLOOD 
HAEMOGLOBIN gm/dl 
TC Cells/mm3 
DC 
NEUTROPHILS % 
LYMPHOCYTES % 
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EOSINOPHILS % 
BASOPHILS % 
MONOCYTES % 
ESR mm/1hr 
CARDIAC ENZYMES : CPK-MB IU/L 
II.URINE 
ALBUMIN 
SUGAR 
MICROSCOPY 
III.BIOCHEMISTRY 
RBS mg/dl 
TOTAL CHOLESTEROL mg/dl 
HDL CHOLESTEROL mg/dl 
LDL CHOLESTEROL mg/dl 
VLDL CHOLESTEROL mg/dl 
TRIGLYCERIDE mg/dl 
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IV.ELECTROCARDIOGRAPHY 
V.ECHOCARDIOGRAPHY 
EJECTION FRACTION 
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CONCLUSIONS 
OTHER RELEVANT INVESTIGATIONS 
DIAGNOSIS 
THROMBOLYSIS - DONE/NOT DONE 
IN HOSPITAL COMPLICATIONS 
CCF/LVF 
Cardiogenic shock 
Arrythmias 
Thromboembolism 
Precarditis 
Rupture of Interventricular septum 
Rupture of papillary muscle 
Aneurysm 
Any other 
FOLLOW UP UPTO TO DATE OF DISCHARGE 
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LIST OF ABBREVIATIONS 
 
 
AMI– Acute myocardial infarction 
 
AF– Atrial Fibrillation 
 
CAD – Coronary Artery Disease 
 
CCF – Congestive Cardiac Failure 
 
CHD – Coronary Heart Disease 
 
CK-MB – Creatinine Kinase-MB 
 
CVD – Cardiovascular diseases 
 
ECG – Electrocardiogram 
 
IHD – Ischemic Heart Disease 
 
LVF – Left ventricular Failure 
 
MR – Mitral Regurgitation 
 
MI – Myocardial infarction 
 
RBS – Random Blood Sugar 
 
SA– Sinoatrial node 
 
STEMI – ST Elevation myocardial infarction 
 
VT – Ventricular Tachycardia 
 
WBC – White Blood Cell 
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1 1490527 34 M Y N Y Y 1 + Y         AW
MI 
50 R 
2 1489271 80 F N N Y N 2 +  Y        IW
MI 
50 R 
3 1487224 36 M Y N N N 2 -     Y     AW
MI 
52 R 
4 1488312 50 M M Y Y Y 1 - Y         AW
MI 
50 R 
5 1484857 37 M Y N Y N 2 +     Y     AS
MI 
52 R 
6 1486695 60 M Y Y N N 3 -   Y       AS
MI 
55 R 
7 1486421 70 F N Y N N 3 +      Y   Y AW
MI 
42 D 
8 1485091 50 F N Y N Y 1 +    Y      IW
MI 
51 R 
9 1482551 74 M Y N N Y 2 -  Y        IW
MI 
48 R 
10 148864 60 F N Y Y N 4 -      Y    RV
MI 
45 D 
11 3400 60 F N Y Y N 1 +    Y      JW
MI 
50 R 
12 8611 65 F N Y Y Y 2 +   Y       AW
MI 
38 D 
13 3425 66 M Y Y Y N 1 + Y         IW
MI 
52 R 
14 3365 53 M Y N N Y 2 -        Y  AS
MI 
58 R 
15 2824 54 M Y N N N 1 +    Y      AW
MI 
50 R 
16 842 72 M N N Y N 1 - Y         AW
MI 
54 R 
17 1200 42 M N N N N 2 +     Y     JW
MI 
55 R 
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18 671 50 M Y Y Y Y 4 +         Y AW
MI 
32 D 
19 1492232 56 M Y N N Y 3 +      Y    AW
MI 
48 R 
20 1490197 65 M N Y N N 2 +     Y     AW
MI 
51 R 
21 7211 85 M N Y N Y 2 -        Y  IW
MI 
50 R 
22 7079 50 M N N N Y 1 +    Y      AW
MI 
54 R 
23 6584 60 F N Y Y Y 2 +  Y        IW
MI 
50 R 
24 5588 66 M Y Y Y Y 3 +     Y     IW
MI 
29 D 
25 5381 55 M Y N N N 1 +    Y      AW
MI 
54 R 
26 5322 28 M Y N N N 1 - Y         AW
MI 
55 R 
27 5216 60 F N Y Y N 3 +   Y       AW
MI 
30 D 
28 4863 75 M N Y Y Y 2 -  Y        AW
MI 
38 R 
29 4378 60 M Y Y Y N 3 -     Y     AW
MI 
33 D 
30 4150 45 M Y N N N 2 +  Y        IW
MI 
48 R 
31 10397 56 M Y N Y Y 2 +  Y        AW
MI 
42 R 
32 9791 55 M N N N N 3 +   Y       IW
MI 
40 R 
33 9782 40 M Y Y Y Y 1 +    Y      IW
MI 
50 R 
34 9006 53 F Y Y N N 1 - Y         IW
MI 
52 R 
35 8445 60 M Y Y N Y 2 +     Y     IW
MI 
54 R 
36 8677 46 M N N Y Y 2 +     Y     AW
MI 
53 R 
37 8025 54 M N N Y Y 3 -         Y AW
MI 
40 D 
38 7325 47 M N N N N 2 +  Y        AW
MI 
55 R 
39 7319 63 M Y Y N N 1 +    Y      AW
MI 
52 R 
40 7470 60 M Y N Y N 1 - Y         IW
MI 
50 R 
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41 14527 62 M Y Y N Y 1 +       Y   AW
MI 
49 R 
42 14292 50 M Y Y N Y 1 +    Y      AW
MI 
52 R 
43 13335 60 M Y Y N Y 2 -  Y       Y AW
MI 
38 D 
44 13076 72 M Y N Y Y 2 +    Y      AW
MI 
53 R 
45 12947 50 M Y Y Y N 1 - Y         IW
MI 
55 R 
46 11653 68 M Y N N N 3 +      Y    IW
MI 
48 R 
47 12040 45 M Y Y Y Y 1 + Y         AW
MI 
53 R 
48 11259 63 M Y Y Y Y 3 +    Y      Y AW
MI 
45 D 
49 10499 56 M Y N Y Y 1 +    Y      AW
MI 
55 R 
50 10449 48 M Y Y Y N 2 -  Y        IW
MI 
50 R 
51 20101 37 M Y N Y N 1 - Y         AW
MI 
50 R 
52 20797 65 M Y Y Y Y 2 +  Y        AW
MI 
48 R 
53 20155 70 F N Y Y Y 2 +     Y    Y AW
MI 
50 D 
54 17671 47 F N N N Y 1 +    Y      IW
MI 
55 R 
55 18558 58 M Y Y N N 3 +        Y  AW
MI 
48 R 
56 18236 65 M Y Y N Y 1 +    Y      AW
MI 
53 R 
57 16903 55 M N N N Y 3 -   Y       AW
MI 
42 D 
58 15651 61 F N Y Y Y 2 +  Y        RV
MI 
50 R 
59 14582 62 M N N N Y 1 +    Y      AW
MI 
55 R 
60 14506 35 M Y Y Y N 2 -        Y  AW
MI 
51 R 
61 28355 80 F N Y N Y 1 +       Y   AW
MI 
50 R 
62 28150 69 F N Y N Y 2 +  Y        AW
MI 
52 R 
63 25264 55 M Y Y Y Y 2 +     Y     AW
MI 
55 R 
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64 25780 76 M Y Y N Y 4 -        Y  AW
MI 
30 D 
65 24792 59 M Y N Y N 1 + Y         AW
MI 
49 R 
66 24453 75 M Y N Y N 1 +    Y      AW
MI 
51 R 
67 20986 56 M N Y Y N 1 + Y         IW
MI 
50 R 
68 22175 67 M Y Y Y Y 4 -         Y AW
MI 
34 D 
69 21912 52 F N Y N N 2 +  Y        AW
MI 
55 R 
70 21260 65 M Y Y Y Y 3 -   Y       AW
MI 
45 R 
71 31158 70 M N Y N Y 1 - Y         AW
MI 
50 R 
72 35661 65 M N Y Y N 2 +    Y      AW
MI 
52 R 
73 35875 53 M Y N Y Y 2 +  Y        AW
MI 
55 R 
74 35097 60 F N Y Y N 1 -    Y      AW
MI 
53 R 
75 33697 57 M Y Y N Y 1 + Y         IW
MI 
50 R 
76 33232 62 M Y N N N 2 +     Y     IW
MI 
48 R 
77 32714 49 F N Y Y N 2 -      Y    IW
MI 
48 D 
78 30922 55 M Y Y Y Y 3 +   Y       IW
MI 
45 R 
79 30102 65 F N Y N Y 2 +     Y     AW
MI 
52 R 
80 28618 55 M Y Y Y Y 1 + Y         IW
MI 
55 R 
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 KEY : 
Y YES 
N NO 
F FEMALE 
M MALE 
D DEATH 
R RECOVERY 
+ THROMOLYSIS DONE 
- THROMOLYSIS NOT 
DONE 
ASMI ANTEROSEPTAL 
MYOCORDIAL 
INFARCTION 
AWMI ANTERIOR WALL 
MYOCORDIAL 
INFARCTION 
IWMI INFERIOR WALL 
MYOCORDIAL 
INFARCTION 
RVMI RVMI RIGHT 
VENTRICULAR 
MYOCARDIAL 
INFARCTION 
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CONSENT FORM 
 
 
 
I __________________________________________  hereby give consent to 
participate in the study conducted by DR .R.VINOTH KANNAN Post graduate in 
the Department of  General Medicine ,Thanjavur Medical College & Hospital, 
Thanjavur – 613004 and to use my personal clinical data and result of investigation 
for the purpose of analysis and to study the nature of disease. I also give consent 
for further investigations 
 
 
Place : 
Date :       Signature of participant 
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INFORMATION SHEET 
 
• We are conducting a prospective study on “A STUDY ON 
PROGNOSTIC SIGNIFICANCE OF WHITE BLOOD CELL COUNT 
AND BLOOD GLUCOSE LEVELS AT ADMISSION IN ST 
ELEVATION MYOCARDIAL INFARCTION” in the Department of 
General Medicine , Thanjavur Medical College & Hospital, Thanjavur – 
613004. 
 
• At the time of announcing the results and suggestions, name and identity of 
the patients will be confidential. 
 
• Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 
• The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may 
aid in the management or treatment.  
 
 
 
 
 
 
 
Signature of investigator  Signature of participant 
 
Date: 
 
